Police & Firemen s Retirement System of New Jersey Boosts Stock Position in Glaukos Corporation $GKOS

Police & Firemen s Retirement System of New Jersey boosted its stake in shares of Glaukos Corporation (NYSE:GKOS) by 19.4% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 12,739 shares of the medical instruments supplier’s stock after acquiring an additional 2,069 shares during the quarter. Police & Firemen s Retirement System of New Jersey’s holdings in Glaukos were worth $1,316,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also modified their holdings of the stock. Geode Capital Management LLC raised its stake in shares of Glaukos by 9.5% during the second quarter. Geode Capital Management LLC now owns 1,330,593 shares of the medical instruments supplier’s stock worth $137,454,000 after purchasing an additional 115,529 shares during the last quarter. Wealth Alliance LLC acquired a new position in Glaukos in the 2nd quarter valued at $235,000. ProShare Advisors LLC raised its position in Glaukos by 7.4% during the 2nd quarter. ProShare Advisors LLC now owns 12,502 shares of the medical instruments supplier’s stock worth $1,291,000 after buying an additional 861 shares during the last quarter. Profund Advisors LLC raised its position in Glaukos by 13.9% during the 2nd quarter. Profund Advisors LLC now owns 2,822 shares of the medical instruments supplier’s stock worth $291,000 after buying an additional 345 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Glaukos in the 2nd quarter worth $1,355,000. Institutional investors and hedge funds own 99.04% of the company’s stock.

Glaukos Price Performance

Shares of NYSE:GKOS opened at $95.26 on Friday. The firm has a market capitalization of $5.47 billion, a price-to-earnings ratio of -61.86 and a beta of 0.81. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.51 and a quick ratio of 4.69. The business’s 50 day simple moving average is $84.38 and its 200-day simple moving average is $91.32. Glaukos Corporation has a 12 month low of $73.16 and a 12 month high of $163.71.

Glaukos (NYSE:GKOS) last issued its quarterly earnings data on Wednesday, October 29th. The medical instruments supplier reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.11. The firm had revenue of $133.54 million during the quarter, compared to analysts’ expectations of $122.55 million. Glaukos had a negative return on equity of 7.53% and a negative net margin of 18.65%.Glaukos’s revenue was up 38.1% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.28) earnings per share. Glaukos has set its FY 2025 guidance at EPS. As a group, equities analysts forecast that Glaukos Corporation will post -1.08 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on GKOS shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Glaukos in a research note on Wednesday, October 8th. Truist Financial set a $120.00 target price on Glaukos in a research report on Thursday, October 30th. BTIG Research raised their price target on Glaukos from $104.00 to $116.00 and gave the company a “buy” rating in a report on Thursday, October 30th. William Blair raised Glaukos to a “strong-buy” rating in a report on Thursday, July 31st. Finally, Needham & Company LLC increased their price objective on Glaukos from $115.00 to $117.00 and gave the stock a “buy” rating in a research report on Thursday, October 30th. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $119.08.

Insider Activity at Glaukos

In related news, COO Joseph E. Gilliam sold 19,340 shares of the stock in a transaction dated Tuesday, November 18th. The shares were sold at an average price of $90.00, for a total value of $1,740,600.00. Following the sale, the chief operating officer directly owned 92,366 shares of the company’s stock, valued at approximately $8,312,940. This represents a 17.31% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 5.80% of the stock is owned by corporate insiders.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.